ArticleOncotarget2018

Combined alkylation and histone deacetylase inhibition with EDO-S101 has significant therapeutic activity against brain tumors in preclinical models.

Yushi Qiu et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.